Prostate Cancer Clinical Trial

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Summary

This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein (SPOP). M1774 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving M1774 may be able to shrink or stabilize refractory SPOP-mutant prostate cancer.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To evaluate the response rate of tuvusertib (ATR inhibitor M1774) in highly refractory prostate cancer.

SECONDARY OBJECTIVES:

I. To evaluate the overall survival (OS) of refractory SPOP-mutant prostate cancer patients receiving tuvusertib (M1774).

II. To evaluate the progression-free survival (PFS) of refractory SPOP-mutant prostate cancer patients receiving M1774.

III. To evaluate the Common Terminology Criteria for Adverse Events (CTCAE) 5.0-defined adverse event (AE) rates of refractory SPOP-mutant prostate cancer patients receiving M1774.

EXPLORATORY OBJECTIVE:

I. To determine changes in SPOP-mutant circulating tumor deoxyribonucleic acid (ctDNA) and SPOP-, ATR-, and ATM-related gene signature changes on ATR inhibition, including RAC1, FDFT1, DHCR24, DHCR7, and MVD.

OUTLINE:

Patients receive tuvusertib orally (PO) every day (QD) on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET)/MRI, PET/CT or ultrasound (U/S) and collection of blood samples throughout the trial.

After completion of study treatment, patients are followed up every 6 months for 2 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Presence of SPOP mutations in prostate cancer cells, as indicated by Next Generation Sequencing (NGS)
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with CT scan, MRI, or calipers by clinical exam
Castrate-range testosterone (< 50 ng/dL) after androgen deprivation therapy (ADT) or orchiectomy
Prior treatment with second generation anti-androgen (2GAA) and taxane- or lutetium-based therapy
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of M1774 in patients < 18 years of age, children are excluded from this study
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
Absolute neutrophil count >= 1,500/mcL
Platelets >= 100,000/mcL
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic-pyruvic transaminase [SGPT]) =< 3 x institutional ULN
Creatinine =< 1.5 × ULN

Creatinine clearance >= 60 mL/min

Creatinine clearance should be measured if estimated glomerular filtration rate (eGFR) is > 60 mL/min
Hemoglobin >= 9.0g/dL
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
The effects of M1774 on the developing human fetus are unknown. For this reason and because ATR inhibitors may be teratogenic (Musson et al., 2022), women of child-bearing potential who are partners of men enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to the study, for the duration of study participation, and 6 months after completion of M1774 administration. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men enrolled on this study must agree to use adequate contraception prior to study entry, for the duration of study participation, and 3 months after completion of M1774 administration
Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion Criteria:

Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
Patients who are receiving any other investigational agents
Patients with uncontrolled intercurrent illness
Patients who cannot discontinue proton pump inhibitors (PPIs). H2 receptor antagonists will not be permitted within 12 hours before dosing of M1774 and until 2 hours after dosing of M1774. Antacids will not be permitted within 2 hours before and 2 hours after administration of M1774
Patients who cannot discontinue drugs that are strong inhibitors of CYP3A4 or CYP1A2
Patients who cannot discontinue drugs that are hMATE1 or hMATE2-Ksubstrates
Patients with a baseline QC interval > 470 msec

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT05828082

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

Mayo Clinic Hospital in Arizona
Phoenix Arizona, 85054, United States More Info
Site Public Contact
Contact
855-776-0015
Jacob Orme
Principal Investigator
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange California, 92868, United States More Info
Site Public Contact
Contact
877-827-8839
[email protected]
Arash Rezazadeh Kalebasty
Principal Investigator
Mayo Clinic in Florida
Jacksonville Florida, 32224, United States More Info
Site Public Contact
Contact
855-776-0015
Jacob Orme
Principal Investigator
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami Florida, 33136, United States More Info
Site Public Contact
Contact
305-243-2647
Janaki N. Sharma
Principal Investigator
Memorial Hospital East
Shiloh Illinois, 62269, United States More Info
Site Public Contact
Contact
314-747-9912
[email protected]
Melissa A. Reimers
Principal Investigator
University of Kansas Cancer Center
Kansas City Kansas, 66160, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Rahul A. Parikh
Principal Investigator
University of Kansas Hospital-Indian Creek Campus
Overland Park Kansas, 66211, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Rahul A. Parikh
Principal Investigator
University of Kansas Hospital-Westwood Cancer Center
Westwood Kansas, 66205, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Rahul A. Parikh
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO
Boston Massachusetts, 02115, United States More Info
Jacob Orme
Contact
507-284-2511
[email protected]
Jacob Orme
Principal Investigator
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Site Public Contact
Contact
855-776-0015
Jacob Orme
Principal Investigator
Siteman Cancer Center at West County Hospital
Creve Coeur Missouri, 63141, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Melissa A. Reimers
Principal Investigator
Washington University School of Medicine
Saint Louis Missouri, 63110, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Melissa A. Reimers
Principal Investigator
Siteman Cancer Center-South County
Saint Louis Missouri, 63129, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Melissa A. Reimers
Principal Investigator
Siteman Cancer Center at Christian Hospital
Saint Louis Missouri, 63136, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Melissa A. Reimers
Principal Investigator
Siteman Cancer Center at Saint Peters Hospital
Saint Peters Missouri, 63376, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Melissa A. Reimers
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Adanma Anji Ayanambakkam Attanathi
Principal Investigator
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh Pennsylvania, 15232, United States More Info
Site Public Contact
Contact
412-647-8073
Priyanka V. Chablani
Principal Investigator
UT Southwestern Simmons Cancer Center - RedBird
Dallas Texas, 75237, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Kevin D. Courtney
Principal Investigator
UT Southwestern/Simmons Cancer Center-Dallas
Dallas Texas, 75390, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Kevin D. Courtney
Principal Investigator
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth Texas, 76104, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Kevin D. Courtney
Principal Investigator
UT Southwestern Clinical Center at Richardson/Plano
Richardson Texas, 75080, United States More Info
Site Public Contact
Contact
972-669-7044
[email protected]
Kevin D. Courtney
Principal Investigator
University of Virginia Cancer Center
Charlottesville Virginia, 22908, United States More Info
Site Public Contact
Contact
434-243-6303
[email protected]
Paul V. Viscuse
Principal Investigator
University of Wisconsin Carbone Cancer Center - University Hospital
Madison Wisconsin, 53792, United States More Info
Site Public Contact
Contact
800-622-8922
[email protected]
Glenn Liu
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT05828082

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.